Palmetto GBA Conveys Validity of Broader Claim for DetermaRx As a Risk of Recurrence Test Expanding Market Utility
IRVINE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey today, announced that the Advisory Panel for clinical diagnostic laboratory tests (CDLT) has unanimously recommended that starting January 2023, the Company’s DetermaRx™ test be cross-walked to CPT code 81522, currently priced at $3,873. Medicare (CMS) will consider this recommendation and is expected to post its preliminary decision in mid-September for public comments and issue a final determination in mid-November.
Separately, the Company announced that Palmetto GBA, a Medicare administrative contractor for the Molecular Diagnostics Services program (MolDX), has conveyed the validity of a Local Coverage Determination (LCD) reconsideration request for broader coverage for DetermaRx to include risk-stratification (in conjunction with TNM staging) to assess the risk of recurrence for the early-stage NSCLC patient to determine the best course of action for patient management.
“On the heels of the VA Contract announcement, we are very excited to share that we have received the confirmation of MolDX’s decision to recommend expanded coverage for DetermaRx pending the required public opinion period. Gaining this expansion as a risk of recurrence test allows physicians the choice of therapy for their high-risk patients, especially important given the interest in using immunotherapy earlier in the disease cycle,” said Ron Andrews, Chief Executive Officer of Oncocyte. “We were also encouraged by the recommendation by CMS’s advisory panel to move DetermaRx into a high-value category and await the posting of the final decision. DetermaRx continues to gain momentum as a powerful indicator of recurrence risk in early-stage NSCLC and to date has impacted the lives of well over 1100 lung cancer patients.”
About Oncocyte Oncocyte is a precision diagnostics company with a mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey.
Through its proprietary tests and pharmaceutical services business, the Company aims to help save lives by accelerating the diagnosis of cancer and advancing cancer care. The Company’s tests are designed to help provide clarity and confidence to physicians and their patients at every stage. DetermaRx™ identifies early-stage lung cancer patients who are at high risk for cancer recurrence and who may benefit from adjuvant chemotherapy. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The Company’s pipeline of tests in development also includes DetermaTx™, which will assess mutational status of a tumor, DetermaCNI™, a blood-based monitoring test, DetermaMx™, a long-term recurrence monitoring test, and VitaGraft™, a blood-based solid organ transplantation monitoring test. In addition, Oncocyte’s pharmaceutical services provide companies that are developing new cancer treatments a full suite of molecular testing services to support the drug development process.
DetermaRx™, DetermaIO™, DetermaTx™, DetermaCNI™, DetermaMx™ and VitaGraft™ are trademarks of Oncocyte Corporation.
Forward-Looking Statements Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” “may,” and similar expressions) are forward-looking statements. These statements include those pertaining to the expectation that CMS will post its preliminary decisions regarding DetermaRx in mid-September for public comments and issue a final determination in mid-November, and potential expanded LCD coverage for DetermaRx, and other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, the potential impact of COVID-19 on Oncocyte or its subsidiaries’ financial and operational results, risks inherent in the development and/or commercialization of diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of Oncocyte’s third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to supply chains, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, obligations to third parties with respect to licensed or acquired technology and products, the need to obtain third party reimbursement for patients’ use of any diagnostic tests Oncocyte or its subsidiaries commercialize in applicable jurisdictions, and risks inherent in strategic transactions such as the potential failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls, potential greater than estimated allocations of resources to develop and commercialize technologies, or potential failure to maintain any laboratory accreditation or certification. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Oncocyte, particularly those mentioned in the “Risk Factors” and other cautionary statements found in Oncocyte’s Securities and Exchange Commission (SEC) filings, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Oncocyte undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Investor & Media Contact Caroline Corner ICR Westwicke Tel: 415.202.5678 caroline.corner@westwicke.com
President Biden is set to visit Ohio for the groundbreaking of Intel’s long-awaited semiconductor manufacturing facility. It’s a victory lap of sorts for the President after he signed the Chips and Science Act of 2022 in August.
As we close in on the final quarter of 2022, investors are looking for an answer to one question: was June’s low the bottom for stocks, or do they have more room to fall? It’s a serious question, and there may be no easy answer. Markets are facing a series of headwinds, from the high inflation and rising interest rates that we’ve grown familiar with to an increasingly strong dollar that will put pressure on the upcoming Q3 earnings. Weighing in on current conditions from Charles Schwab, the $8 t
NIO Inc. stock is trending on the Yahoo Finance Platform. Here is a visualization of $NIO performance over time, how that performance compares to the wider industry, and analyst projections for the current quarter.Check out the ticker page here.
Nursing homes and debt collectors are billing and suing long-term-care residents’ family members and friends, demanding payments for debts these individuals don’t legally owe, consumer attorneys and federal regulators are claiming. Under federal law, nursing homes participating in Medicare and Medicaid can’t make such provisions a condition of admission or continued stay in the facility.
Bill Gates looks for income, too. This is how he gets it.
The S&P 500 is on again, off again all year. But investors clearly have a "buy list" of stocks they want to own when the rally looks real.
Congressional Democrats want to slam shut a tax loophole known as the "backdoor" Roth IRA. In one of several proposed changes that target the retirement accounts of wealthy Americans, Democrats on the House Ways and Means Committee want to prohibit people … Continue reading → The post Democrats Want to End This Lucrative Retirement Account Loophole appeared first on SmartAsset Blog.
Tough times ahead. But you don't need to sell it all.
During tricky market conditions, it can be helpful to follow professional investors who are focused on the long term.
A strong bearish trend defined the markets in the first half of the year; since then, the key point has been volatility. Stocks hit a bottom back in June, when the S&P 500 dropped into the 3,600s. That has proven to be a support level in the last two months, and at least one strategist believes that the market won’t be testing those lows again this year. JPMorgan's Jason Hunter believes that inflation may have peaked, and that the upcoming CPI report will provide additional evidence of that. “We
Berkshire Hathaway is on pace to collect $6.07 billion in dividend income over the next 12 months. Just five holdings will account for 71% of total payouts.
(Bloomberg) -- In a week that saw discretionary buyers beat a quick retreat from risky assets, another set of traders stood up to halt a three-week plunge in the S&P 500: those with little choice but to buy.Most Read from BloombergCharles Becomes King as the Face of a Nation ChangesDouble Rainbow Appears Over Buckingham Palace as Crowd Gathers to Mourn QueenUkraine Army’s Breakthrough in North Threatens Russian GripQueen Elizabeth’s Doctors Are Concerned for Her HealthQueen Elizabeth II, Britain
It's time to be extra picky.
The bad news just doesn't seem to be stopping for Nvidia (NASDAQ: NVDA). The graphics cards specialist received another big blow last week after the U.S. government imposed restrictions on sales of data center chips to China, Hong Kong, and Russia. According to a filing with the SEC, Nvidia reported that the U.S. government has "imposed a new license requirement, effective immediately, for any future export to China (including Hong Kong) and Russia of the Company's A100 and forthcoming H100 integrated circuits."
Nio (NYSE: NIO) reported increasing losses in its second-quarter earnings report this week, but investors are shrugging that off, sending shares soaring Friday morning. Although its profit margins have been on a downward trend, new models being launched could turn that around in the coming years. Consumer prices in China increased at a slower pace than many expected in August, and producer inflation sank to the lowest level since February 2021, reports Reuters.
AT&T income-hungry shareholders should have seen it coming. In April last year, a month before announcing the spinoff of its media division to shareholders in the form of shares of a 71% stake in the newly created Warner Bros. Discovery Chief Executive Officer John Stankey assured investors that “our deliberate capital-allocation plan allowed us to invest and sustain our dividend at current levels, which we believe is attractive.” AT&T’s eventual failure to raise the dividend in 2021 broke a 34-year streak and saw it booted out of the vaunted S&P 500 Dividend Aristocrats Index.
These stocks have what it takes to provide shareholders solid returns if they take a long-term view on investing.
Deciding when to time your retirement plan withdrawals matters for determining how long your money will last and what you'll pay in taxes for those distributions. If you have a 401(k) at work, you might follow the Rule of 55 … Continue reading → The post Rule of 55 vs. 72(t): Retirement Plan Withdrawals appeared first on SmartAsset Blog.
On Friday, the company unveiled the Robinhood Investor Index, which captures how customers invest based on the top 100 most owned stocks on the platform.
Berkshire Hathaway's (NYSE: BRK.A)(NYSE: BRK.B) CEO Warren Buffett is one of the best investors of our lifetime. Buffett stands out, in part, because he doesn't tend to follow the crowd, doesn't fear market crashes, and has a knack for putting his cash to work when everyone else is fearful. Buffett has explained that he looks to buy quality companies with management teams he likes and that he buys with the intention of holding on to these investments for years or even decades.